Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Type

Type

Guidance programme

Advice programme

Showing 11 to 20 of 60

TitleReference numberPublishedLast updated
Talazoparib for treating HER2-negative advanced breast cancer with germline BRCA mutationsTA952
Familial breast cancer: classification, care and managing breast cancer and related risks in people with a family history of breast cancerCG164
Olaparib for adjuvant treatment of BRCA mutation-positive HER2-negative high-risk early breast cancer after chemotherapyTA886
Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatmentsTA862
Pembrolizumab for neoadjuvant and adjuvant treatment of triple-negative early or locally advanced breast cancerTA851
Palbociclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapyTA836
Magtrace and Sentimag system for locating sentinel lymph nodes for breast cancerHTG642
Contrast-enhanced spectral mammography for breast cancerMIB304
Sacituzumab govitecan for treating unresectable triple-negative advanced breast cancer after 2 or more therapiesTA819
Alpelisib with fulvestrant for treating hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced breast cancerTA816

Results per page

  1. 10
  2. 25
  3. 50
  4. All